pharma · Persistent Corneal Epithelial Defect (PCED) · Recent onset Type 1 Diabetes
Doppel Farmaceutici
Dompe' Farmaceutici S.p.A.
Dompe' Farmaceutici S.p.A is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Persistent Corneal Epithelial Defect (PCED), Recent onset Type 1 Diabetes, Spastic Cerebral Palsy, C
Via Martiri delle Foibe 1, Cortemaggiore (PC), Emilia-Romagna 29016, IT, napoli HQ
1994 Founded
393 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Via Martiri delle Foibe 1, Cortemaggiore (PC), Emilia-Romagna 29016, IT, napoli
- Founded
- 1994
- Employees
- 393
- Programs
- 11
- Drugs
- 14
- Patents
- 0
Vehicle, Cenegermin
Phase 2 · small molecule · Subacute Moderate to Severe Traumatic Brain Injury (TBI)
Vehicle, Cenegermin for Subacute Moderate to Severe Traumatic Brain Injury (TBI) is a Phase 2 program (small_molecule) at Dompe' Farmaceutici S.p.A. with 1 ClinicalTrials.gov record(s).
Internal code NGF-TBI-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Dompe' Farmaceutici S.p.A.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Subacute Moderate to Severe Traumatic Brain Injury (TBI)
- Status
- active
- Trials
- 1